Trial Profile

Clinical trial of Psilocybin in the Treatment of Traumatic Brain Injury and stroke

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Stroke; Traumatic brain injuries
Focus Adverse reactions
Sponsors Revive Therapeutics

Most Recent Events

15 Aug 2021 New trial record
10 Aug 2021 According to a Revive Therapeutics media release, the Company is proceeding to an FDA clinical study to be conducted at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy.
10 Aug 2021 According to a Revive Therapeutics media release, the company plans to start patient enrollment in this study in the Q4 of 2021

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com